Please login to the form below

risankizumab

This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

news. Quick take-up of new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) have encouraged AbbVie to predict the pair will together make around $1.7bn in sales this year, well

Latest news

Cosentyx, Entresto drive topline growth for Novartis in Q4

However, in head-to-head trials with both AbbVie’s Humira (adalimumab) and Skyrizi (risankizumab), Cosentyx failed to show superiority – a potential sign of trouble ahead as the psoriasis/biologic market
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi (risankizumab) against Novartis’ blockbuster IL-17 inhibitor Cosentyx (secukinumab) – which has sales currently running at around $1bn a quarter – and
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis.
J&J splashes $750m on anti-inflammatory drug bermekimab

secukinumab) and AbbVie’s Skyrizi (risankizumab).
Novartis’ Cosentyx misses the mark in Humira head-to-head

This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Sales are projected at $1.93bn for 2013. Skyrizi (risankizumab) treats psoriasis.
Drug launches to watch in 2019

It announced the filing of upadacitinib in the US and Europe on 20 December, with the filing of risankizumab expected early this year. ... The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s treatment, compared to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

The concordance conundrum: understanding the complexities of behaviour change: Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue: Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...